Theratechnologies Files 6-K Report
| Field | Detail |
|---|---|
| Company | Theratechnologies Inc. |
| Form Type | 6-K |
| Filed Date | Sep 2, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: 6-K, regulatory-filing, press-release
TL;DR
Theratechnologies filed a 6-K on 9/2/25 with a press release attached.
AI Summary
Theratechnologies Inc. filed a Form 6-K on September 2, 2025, reporting information for the month of September 2025. The filing includes a press release dated September 2, 2025, as Exhibit 99.1. The company is a foreign private issuer based in Montreal, Quebec, Canada, and is incorporated in A8.
Why It Matters
This filing provides an update on Theratechnologies Inc.'s activities and disclosures as a foreign private issuer, which is important for investors tracking the company's regulatory compliance and recent announcements.
Risk Assessment
Risk Level: low — This is a routine filing (6-K) that typically contains press releases or other periodic disclosures from foreign private issuers, not indicating significant new risks.
Key Players & Entities
- Theratechnologies Inc. (company) — Filer of the report
- September 2, 2025 (date) — Date of the press release and filing
- Jocelyn Lafond (person) — General Counsel and Corporate Secretary who signed the report
FAQ
What type of report is Theratechnologies Inc. filing?
Theratechnologies Inc. is filing a Form 6-K report.
When was this Form 6-K filed?
The Form 6-K was filed on September 2, 2025.
What is the primary exhibit included in this filing?
The primary exhibit is a Press Release dated September 2, 2025, designated as Exhibit No. 99.1.
Where is Theratechnologies Inc. headquartered?
Theratechnologies Inc. is headquartered in Montreal, Quebec, Canada.
Does Theratechnologies Inc. file annual reports under Form 20-F or 40-F?
The filing indicates that the registrant files annual reports under cover of Form 20-F.
Filing Stats: 151 words · 1 min read · ~1 pages · Grade level 11.1 · Accepted 2025-09-02 13:26:55
Filing Documents
- d77450d6k.htm (6-K) — 8KB
- d77450dex991.htm (EX-99.1) — 22KB
- g77450g0703200507393.jpg (GRAPHIC) — 3KB
- 0001193125-25-193796.txt ( ) — 36KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. THERATECHNOLOGIES INC. By: /s/ Jocelyn Lafond Name: Jocelyn Lafond Title: General Counsel and Corporate Secretary Date: September 2, 2025